Drug Profile


Alternative Names: BB 2516; TA 2516

Latest Information Update: 22 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Schering-Plough; Tanabe Seiyaku; Vernalis
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Glioma; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 22 Mar 2004 Discontinued - Phase-II for Gastric cancer in Japan (PO)
  • 22 Mar 2004 Discontinued - Phase-II for Head and neck cancer in USA (PO)
  • 22 Mar 2004 Discontinued - Phase-II for Lung cancer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top